Table 1

SARS-CoV-2 vaccination after haematological autologous stem cell transplantation for systemic sclerosis

Patient1234567Average
Age6959563943493750.2±11
SexFFFFMFF86% F
SerologyScl-70RNAPOLIIIRNAPOLIIIScl-70Scl-70Scl-70Scl-70
mRSS baseline332131281530623±9
Lung fibrosisYesYesYesYesYesYesYes
Cardiac involvementNoNoNoNoYesYesYes
Treatment before AHSCTCYCMMFMTX +MMFMMFMMFMMF +rituxMMF +ritux
Time from AHSCT (months)6048302418123Median 24 m
Conditioning
Cyc (total dose)200 mg/kg200 mg/kg200 mg/kg200 mg/kg120 mg/kg120 mg/kg120 mg/kg
Influenza (total dose)NoNoNoNo90 mg/m290 mg/m290 mg/m2
Rabbit ATG6 mg/kg6 mg/kg6 mg/kg6 mg/kg6 mg/kg6 mg/kg6 mg/kg
CD 34+ selectionNoNoNoNoNoNoYes
Time to engraftment (days)
Day of vaccination:
910915121110
 -CD 20+ cells/mm3
 (% of lymphocytes)
 Normal >1%
100 (8%)204 (15%)152 (10%)386 (14%)161 (12%)232 (11%)220 (22%)207±90 (13±4.5%)
 -CD 4+
 (cells/mm3)
 Adverse response
266
Tiredness
480
No
332
No
990
No
219
No
370
No
95
No
393±290
SARS-COV-2 IgG ABYesYesYesYesYesYesNo86%
Titres igG AU/mL
Vaccinated (>150 AU/mL)
21 18739035567346024 8615830<219258±9653
Healthy controls1234567
Age6359554440543449.8±10
SexFFFFMFF86% F
-CD 20+ cells/mm3
(% of lymphocytes)
Normal >1%
168 (12%)234 (9%)124 (10%)257 (10%)153 (10%)206 (9%)98 (10%)177±58
(10%±1%)
CD 4+
(cells/mm3)
619156458711586901422551921±446
Adverse responseNoNoNoNoNoNoNo
SARS-COV-2 IgG ABYesYesYesYesYesYesYes100%
Titers igG AU/mL vaccinated (>150 AU/mL)871860 00024 7393958327411 167953017 340±18.6
  • Serum antibodies after vaccination against s1 protein were evaluated by chemiluminescent microparticle immunoassay against s1 subunit of the spike protein using Abbott architect system.

  • AHSCT, autologous haematological stem cell transplantation; ATG, rabbit antithymocyte globulins; cyc, cyclophosphamide; F, female; flu, fludarabine; M, male; MMF, mycophenolate mofetil; mRSS, modified Rodnan Skin Score; MTX, methotrexate; ritux, rituximab; RNAPOLIII, RNA polymerase III; SCL-70, scleroderma70.